Skip to main content
Top
Published in: Clinical and Experimental Medicine 2/2017

Open Access 01-05-2017 | Original Article

Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C

Authors: Anna Wróblewska, Agnieszka Bernat, Anna Woziwodzka, Joanna Markiewicz, Tomasz Romanowski, Krzysztof P. Bielawski, Tomasz Smiatacz, Katarzyna Sikorska

Published in: Clinical and Experimental Medicine | Issue 2/2017

Login to get access

Abstract

Single nucleotide polymorphisms (SNPs) within DNA region containing interferon lambda 3 (IFNL3) and IFNL4 genes are prognostic factors of treatment response in chronic hepatitis C (CHC). Iron overload, frequently diagnosed in CHC, is associated with unfavorable disease course and a risk of carcinogenesis. Its etiology and relationship with the immune response in CHC are not fully explained. Our aim was to determine whether IFNL polymorphisms in CHC patients associate with body iron indices, and whether they are linked with hepatic expression of genes involved in iron homeostasis and IFN signaling. For 192 CHC patients, four SNPs within IFNL3-IFNL4 region (rs12979860, rs368234815, rs8099917, rs12980275) were genotyped. In 185 liver biopsies, histopathological analyses were performed. Expression of five mRNAs and three long non-coding RNAs (lncRNAs) was determined with qRT-PCR in 105 liver samples. Rs12979860 TT or rs8099917 GG genotypes as well as markers of serum and hepatocyte iron overload associated with higher activity of gamma-glutamyl transpeptidase and liver steatosis. The presence of two minor alleles in any of the tested SNPs predisposed to abnormally high serum iron concentration and correlated with higher hepatic expression of lncRNA NRIR. On the other hand, homozygosity in any major allele associated with higher viral load. Patients bearing rs12979860 CC genotype had lower hepatic expression of hepcidin (HAMP; P = 0.03). HAMP mRNA level positively correlated with serum iron indices and degree of hepatocyte iron deposits. IFNL polymorphisms influence regulatory pathways of cellular response to IFN and affect body iron balance in chronic hepatitis C virus infection.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wedemeyer H, Duberg AS, Buti M, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21(Suppl 1):60–89.CrossRefPubMed Wedemeyer H, Duberg AS, Buti M, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21(Suppl 1):60–89.CrossRefPubMed
2.
go back to reference Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.CrossRefPubMed Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.CrossRefPubMed
3.
go back to reference Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100–4.CrossRefPubMed Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100–4.CrossRefPubMed
4.
go back to reference Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–9.CrossRefPubMed Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–9.CrossRefPubMed
5.
go back to reference Urban TJ, Thompson AJ, Bradrick SS, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 2010;52(6):1888–96.CrossRefPubMedPubMedCentral Urban TJ, Thompson AJ, Bradrick SS, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 2010;52(6):1888–96.CrossRefPubMedPubMedCentral
6.
go back to reference Duong FH, Trincucci G, Boldanova T, et al. IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies. J Exp Med. 2014;211(5):857–68.CrossRefPubMedPubMedCentral Duong FH, Trincucci G, Boldanova T, et al. IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies. J Exp Med. 2014;211(5):857–68.CrossRefPubMedPubMedCentral
7.
go back to reference Tillmann HL, Patel K, Muir AJ, et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol. 2011;55(6):1195–200.CrossRefPubMedPubMedCentral Tillmann HL, Patel K, Muir AJ, et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol. 2011;55(6):1195–200.CrossRefPubMedPubMedCentral
8.
go back to reference Rojas Á, del Campo JA, Maraver M, et al. Hepatitis C virus infection alters lipid metabolism depending on IL28B polymorphism and viral genotype and modulates gene expression in vivo and in vitro. J Viral Hepat. 2014;21(1):19–24.CrossRefPubMed Rojas Á, del Campo JA, Maraver M, et al. Hepatitis C virus infection alters lipid metabolism depending on IL28B polymorphism and viral genotype and modulates gene expression in vivo and in vitro. J Viral Hepat. 2014;21(1):19–24.CrossRefPubMed
9.
go back to reference Sato M, Kondo M, Tateishi R, et al. Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis. PLoS One. 2014;9(3):e91822.CrossRefPubMedPubMedCentral Sato M, Kondo M, Tateishi R, et al. Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis. PLoS One. 2014;9(3):e91822.CrossRefPubMedPubMedCentral
10.
go back to reference Amanzada A, Kopp W, Spengler U, Ramadori G, Mihm S. Interferon-λ4 (IFNL4) transcript expression in human liver tissue samples. PLoS One. 2013;8(12):e84026.CrossRefPubMedPubMedCentral Amanzada A, Kopp W, Spengler U, Ramadori G, Mihm S. Interferon-λ4 (IFNL4) transcript expression in human liver tissue samples. PLoS One. 2013;8(12):e84026.CrossRefPubMedPubMedCentral
11.
go back to reference Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a novel interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45(2):164–71.CrossRefPubMedPubMedCentral Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a novel interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45(2):164–71.CrossRefPubMedPubMedCentral
12.
go back to reference Bonkovsky HL, Naishadham D, Lambrecht RW, et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology. 2006;131(5):1440–51.CrossRefPubMed Bonkovsky HL, Naishadham D, Lambrecht RW, et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology. 2006;131(5):1440–51.CrossRefPubMed
13.
go back to reference Di Bisceglie AM, Bonkovsky HL, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology. 2000;32(1):135–8.CrossRefPubMed Di Bisceglie AM, Bonkovsky HL, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology. 2000;32(1):135–8.CrossRefPubMed
14.
go back to reference Fujita N, Horiike S, Sugimoto R, et al. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic Biol Med. 2007;42(3):353–62.CrossRefPubMed Fujita N, Horiike S, Sugimoto R, et al. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic Biol Med. 2007;42(3):353–62.CrossRefPubMed
15.
16.
go back to reference Sikorska K, Stalke P, Izycka-Swieszewska E, Romanowski T, Bielawski KP. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C. Med Sci Monit. 2010;16(3):CR137–43.PubMed Sikorska K, Stalke P, Izycka-Swieszewska E, Romanowski T, Bielawski KP. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C. Med Sci Monit. 2010;16(3):CR137–43.PubMed
17.
go back to reference Fillebeen C, Pantopoulos K. Iron inhibits replication of infectious hepatitis C virus in permissive Huh7.5.1 cells. J Hepatol. 2010;53(6):995–9.CrossRefPubMed Fillebeen C, Pantopoulos K. Iron inhibits replication of infectious hepatitis C virus in permissive Huh7.5.1 cells. J Hepatol. 2010;53(6):995–9.CrossRefPubMed
18.
19.
go back to reference Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037–44.CrossRefPubMedPubMedCentral Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037–44.CrossRefPubMedPubMedCentral
20.
go back to reference Fujita N, Sugimoto R, Urawa N, et al. Influence of phlebotomy on iron-related gene expression levels in the livers of patients with chronic hepatitis C. J Gastroenterol. 2007;42(4):326–7.CrossRefPubMed Fujita N, Sugimoto R, Urawa N, et al. Influence of phlebotomy on iron-related gene expression levels in the livers of patients with chronic hepatitis C. J Gastroenterol. 2007;42(4):326–7.CrossRefPubMed
21.
go back to reference Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology. 2008;48(5):1420–9.CrossRefPubMed Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology. 2008;48(5):1420–9.CrossRefPubMed
22.
go back to reference Sikorska K, Romanowski T, Stalke P, Izycka Swieszewska E, Bielawski KP. Association of hepcidin mRNA expression with hepatocyte iron accumulation and effects of antiviral therapy in chronic hepatitis C infection. Hepat Mon. 2014;14(11):e21184.PubMedPubMedCentral Sikorska K, Romanowski T, Stalke P, Izycka Swieszewska E, Bielawski KP. Association of hepcidin mRNA expression with hepatocyte iron accumulation and effects of antiviral therapy in chronic hepatitis C infection. Hepat Mon. 2014;14(11):e21184.PubMedPubMedCentral
23.
go back to reference Kambara H, Niazi F, Kostadinova L, et al. Negative regulation of the interferon response by an interferon-induced long non-coding RNA. Nucl Acids Res. 2014;42(16):10668–80.CrossRefPubMedPubMedCentral Kambara H, Niazi F, Kostadinova L, et al. Negative regulation of the interferon response by an interferon-induced long non-coding RNA. Nucl Acids Res. 2014;42(16):10668–80.CrossRefPubMedPubMedCentral
24.
go back to reference Ouyang J, Zhu X, Chen Y, et al. NRAV, a long noncoding RNA, modulates antiviral responses through suppression of interferon-stimulated gene transcription. Cell Host Microbe. 2014;16(5):616–26.CrossRefPubMed Ouyang J, Zhu X, Chen Y, et al. NRAV, a long noncoding RNA, modulates antiviral responses through suppression of interferon-stimulated gene transcription. Cell Host Microbe. 2014;16(5):616–26.CrossRefPubMed
25.
go back to reference Barriocanal M, Carnero E, Segura V, Fortes P. Long non-coding RNA BST2/BISPR is induced by IFN and regulates the expression of the antiviral factor tetherin. Front Immunol. 2014;5:655.PubMed Barriocanal M, Carnero E, Segura V, Fortes P. Long non-coding RNA BST2/BISPR is induced by IFN and regulates the expression of the antiviral factor tetherin. Front Immunol. 2014;5:655.PubMed
26.
go back to reference Beaton MD, Adams PC. Treatment of hyperferritinemia. Ann Hepatol. 2012;11(3):294–300.PubMed Beaton MD, Adams PC. Treatment of hyperferritinemia. Ann Hepatol. 2012;11(3):294–300.PubMed
27.
go back to reference Sikorska K, Bielawski KP, Stalke P, et al. HFE gene mutations in Polish patients with disturbances of iron metabolism: an initial assessment. Int J Mol Med. 2005;16(6):1151–6.PubMed Sikorska K, Bielawski KP, Stalke P, et al. HFE gene mutations in Polish patients with disturbances of iron metabolism: an initial assessment. Int J Mol Med. 2005;16(6):1151–6.PubMed
28.
go back to reference Gaunt TR, Rodriguez S, Zapata C, Day IN. MIDAS: software for analysis and visualisation of interallelic disequilibrium between multiallelic markers. BMC Bioinform. 2006;7:227.CrossRef Gaunt TR, Rodriguez S, Zapata C, Day IN. MIDAS: software for analysis and visualisation of interallelic disequilibrium between multiallelic markers. BMC Bioinform. 2006;7:227.CrossRef
29.
go back to reference Lange CM, Kutalik Z, Morikawa K, et al. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology. 2012;55(4):1038–47.CrossRefPubMed Lange CM, Kutalik Z, Morikawa K, et al. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology. 2012;55(4):1038–47.CrossRefPubMed
30.
go back to reference Everhart JE, Wright EC. Association of γ-glutamyltransferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Hepatology. 2013;57(5):1725–33.CrossRefPubMedPubMedCentral Everhart JE, Wright EC. Association of γ-glutamyltransferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Hepatology. 2013;57(5):1725–33.CrossRefPubMedPubMedCentral
31.
go back to reference Cherayil BJ. Iron and immunity: immunological consequences of iron deficiency and overload. Arch Immunol Ther Exp (Warsz). 2010;58(6):407–15.CrossRef Cherayil BJ. Iron and immunity: immunological consequences of iron deficiency and overload. Arch Immunol Ther Exp (Warsz). 2010;58(6):407–15.CrossRef
33.
go back to reference Recalcati S, Locati M, Marini A, et al. Differential regulation of iron homeostasis during human macrophage polarized activation. Eur J Immunol. 2010;40(3):824–35.CrossRefPubMed Recalcati S, Locati M, Marini A, et al. Differential regulation of iron homeostasis during human macrophage polarized activation. Eur J Immunol. 2010;40(3):824–35.CrossRefPubMed
34.
go back to reference Ryan JD, Altamura S, Devitt E, et al. Pegylated interferon-alpha induced hypoferremia is associated with the immediate response to treatment in hepatitis C. Hepatology. 2012;56(2):492–500.CrossRefPubMed Ryan JD, Altamura S, Devitt E, et al. Pegylated interferon-alpha induced hypoferremia is associated with the immediate response to treatment in hepatitis C. Hepatology. 2012;56(2):492–500.CrossRefPubMed
35.
go back to reference Cunningham-Rundles S, Giardina PJ, Grady RW, Califano C, McKenzie P, De Sousa M. Effect of transfusional iron overload on immune response. J Infect Dis. 2000;182(Suppl 1):S115–21.CrossRefPubMed Cunningham-Rundles S, Giardina PJ, Grady RW, Califano C, McKenzie P, De Sousa M. Effect of transfusional iron overload on immune response. J Infect Dis. 2000;182(Suppl 1):S115–21.CrossRefPubMed
36.
go back to reference Ezoe S, Yokota T, Ishibashi T, Oritani K, Kanakura Y. Iron overload effects on immune system through the cytokine secretion by macrophage. Blood. 2013;122(21):1047. Ezoe S, Yokota T, Ishibashi T, Oritani K, Kanakura Y. Iron overload effects on immune system through the cytokine secretion by macrophage. Blood. 2013;122(21):1047.
37.
go back to reference Hao C, Zhou Y, He Y, et al. Imbalance of regulatory T cells and T helper type 17 cells in patients with chronic hepatitis C. Immunology. 2014;143(4):531–8.CrossRefPubMedPubMedCentral Hao C, Zhou Y, He Y, et al. Imbalance of regulatory T cells and T helper type 17 cells in patients with chronic hepatitis C. Immunology. 2014;143(4):531–8.CrossRefPubMedPubMedCentral
38.
go back to reference Kohjima M, Yoshimoto T, Enjoji M, et al. Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver. World J Gastroenterol. 2015;21(11):3291–9.PubMedPubMedCentral Kohjima M, Yoshimoto T, Enjoji M, et al. Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver. World J Gastroenterol. 2015;21(11):3291–9.PubMedPubMedCentral
39.
go back to reference Fujita N, Sugimoto R, Motonishi S, et al. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol. 2008;49(5):702–10.CrossRefPubMed Fujita N, Sugimoto R, Motonishi S, et al. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol. 2008;49(5):702–10.CrossRefPubMed
40.
go back to reference Pfeffer LM, Li K, Fleckenstein JF, et al. An interferon response gene signature is associated with the therapeutic response of hepatitis c patients. Shoukry NH, ed. PLoS One. 2014;9(8):e104202.CrossRefPubMedPubMedCentral Pfeffer LM, Li K, Fleckenstein JF, et al. An interferon response gene signature is associated with the therapeutic response of hepatitis c patients. Shoukry NH, ed. PLoS One. 2014;9(8):e104202.CrossRefPubMedPubMedCentral
41.
go back to reference Rogalska-Taranta M, Markova AA, Taranta A, et al. Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism. J Leukoc Biol. 2015;98(2):283–94.CrossRefPubMed Rogalska-Taranta M, Markova AA, Taranta A, et al. Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism. J Leukoc Biol. 2015;98(2):283–94.CrossRefPubMed
42.
go back to reference Dill MT, Duong FH, Vogt JE, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology. 2011;140(3):1021–31.CrossRefPubMed Dill MT, Duong FH, Vogt JE, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology. 2011;140(3):1021–31.CrossRefPubMed
43.
go back to reference Howell CD, Gorden A, Ryan KA, et al. Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J Hepatol. 2012;56(3):557–63.CrossRefPubMed Howell CD, Gorden A, Ryan KA, et al. Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J Hepatol. 2012;56(3):557–63.CrossRefPubMed
44.
go back to reference Naggie S, Osinusi A, Katsounas A, et al. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology. 2012;56(2):444–54.CrossRefPubMedPubMedCentral Naggie S, Osinusi A, Katsounas A, et al. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology. 2012;56(2):444–54.CrossRefPubMedPubMedCentral
45.
go back to reference Kambara H, Gunawardane L, Zebrowski E, et al. Regulation of Interferon-Stimulated Gene BST2 by a lncRNA Transcribed from a Shared Bidirectional Promoter. Front Immunol. 2014;5:676.PubMed Kambara H, Gunawardane L, Zebrowski E, et al. Regulation of Interferon-Stimulated Gene BST2 by a lncRNA Transcribed from a Shared Bidirectional Promoter. Front Immunol. 2014;5:676.PubMed
Metadata
Title
Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C
Authors
Anna Wróblewska
Agnieszka Bernat
Anna Woziwodzka
Joanna Markiewicz
Tomasz Romanowski
Krzysztof P. Bielawski
Tomasz Smiatacz
Katarzyna Sikorska
Publication date
01-05-2017
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 2/2017
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-016-0423-4

Other articles of this Issue 2/2017

Clinical and Experimental Medicine 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.